Back to search
FDAFDA · Food and drugs·Recall number D-0875-2022

GaviLyte -C (Polyethylene Glycol 3350, 240 g) and electrolytes for Oral Solution, USP with flavor pack NDC# 43386-060-19

Published May 25, 2022 · Recall initiated: April 27, 2022

Summary

FDA records drug Class II recall D-0875-2022, published May 25, 2022 and initiated April 27, 2022. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 26,910 bottles; Lot: Lot # S001132, exp. date July 2022 NDC # 43386-060-19. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Stability Specification

What to do

Voluntary: Firm initiated · Letter

Get an email if GAVILYTE - C has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
GAVILYTE - C
Manufacturer
Lupin Pharmaceuticals Inc.
Distributor
Product was distributed nationwide, including Puerto Rico.
Lot
Lot # S001132, exp. date July 2022 NDC # 43386-060-19
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was GaviLyte -C (Polyethylene Glycol 3350, 240 g) and electrolytes for Oral Solution, USP with flavor pack NDC# 43386-060-19 recalled?

Yes. FDA published recall D-0875-2022 on May 25, 2022. Reported hazard: Failed Stability Specification

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: GAVILYTE - C.